ERBB2 and cancer: Also, we proved that the combined treatment of cancer cells with the highly efficacious anti-EGFR CL4 2’fluoro-pyrimidines RNA aptamer and either an anti-HER2 (Erb-hcAb) antibody [93] or the immunomodulators anti-PD-L1 (10_12 mAb) [93] or anti-CTL4 (ipilimumab) mAbs [94] resulted in more efficient killing of cancer cells than single treatments.